New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
06:10 EDTSGYPSynergy Pharmaceuticals' plecanatide shows positive results in Phase 2B study
Synergy Pharmaceuticals announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation. The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement frequency – the study’s primary endpoint – and was safe and well tolerated. The most common event was diarrhea, which occurred in 9.3% of the 3.0mg plecanatide-treated patients. The company intends to initiate pivotal phase 3 trials in IBS-C patients in 2H14.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:18 EDTSGYPSynergy Pharmaceuticals files $250M mixed securities shelf
Subscribe for More Information
June 24, 2015
05:59 EDTSGYPStocks with implied volatility below IV index mean; SGYP WMB
Subscribe for More Information
June 23, 2015
10:30 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
09:14 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
06:36 EDTSGYPSynergy Pharmaceuticals volatility elevated
Subscribe for More Information
06:02 EDTSGYPSynergy Pharma begins second of two Phase 3 clinical trials of plecanatide
Synergy Pharmaceuticals announced the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation, or IBS-C. The phase 3 IBS-C program includes two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the U.S. and each trial is expected to enroll approximately 1050 adult patients with IBS-C.
June 22, 2015
15:41 EDTSGYPSynergy Pharmaceuticals volatility elevated on sharp rally
Synergy Pharmaceuticals July is at 134, October is at 95; compared to its 52-week range of 72 to 158; suggesting large near term price move movement.
10:21 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use